AM-Pharma reports positive results from recAP Phase We trial for Acute Kidney Injury AM-Pharma B.

AM-Pharma reports positive results from recAP Phase We trial for Acute Kidney Injury AM-Pharma B.V., a biopharmaceutical company centered on the development of recAP for inflammatory indications, announces the total results of its Stage I trial with both solitary and multiple ascending doses, which demonstrate that recAP is definitely safe and well tolerated at all doses. Altogether 50 healthy man and female volunteers were contained in the randomised, double-blind, placebo-controlled, first-in-human, solitary and multiple dosage escalation study, to investigate basic safety, tolerability, and pharmacokinetics of recAP intravenously administered.And see our popular CounterThink cartoons here:.

African-American women less likely to reduce drinking during pregnancy New Saint Louis University research found that although white women will drink or binge drink ahead of pregnancy, African-American women are less inclined to reduce drinking during pregnancy, which might be linked to a higher rate of fetal alcohol syndrome among the populace. The findings might help describe the disparities in FAS rates between white and African-American populations, while also drawing focus on the need for alcoholic beverages education interventions and programs for at-risk women.D., director for research in the division of community and family medicine at Saint Louis University and a study author.